These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 27520705)

  • 1. IAP antagonists Birinapant and AT-406 efficiently synergise with either TRAIL, BRAF, or BCL-2 inhibitors to sensitise BRAFV600E colorectal tumour cells to apoptosis.
    Perimenis P; Galaris A; Voulgari A; Prassa M; Pintzas A
    BMC Cancer; 2016 Aug; 16():624. PubMed ID: 27520705
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sensitization of glioblastoma cells to TRAIL-induced apoptosis by IAP- and Bcl-2 antagonism.
    Lincoln FA; Imig D; Boccellato C; Juric V; Noonan J; Kontermann RE; Allgöwer F; Murphy BM; Rehm M
    Cell Death Dis; 2018 Nov; 9(11):1112. PubMed ID: 30385739
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Smac mimetics in combination with TRAIL selectively target cancer stem cells in nasopharyngeal carcinoma.
    Wu MS; Wang GF; Zhao ZQ; Liang Y; Wang HB; Wu MY; Min P; Chen LZ; Feng QS; Bei JX; Zeng YX; Yang D
    Mol Cancer Ther; 2013 Sep; 12(9):1728-37. PubMed ID: 23699656
    [TBL] [Abstract][Full Text] [Related]  

  • 4. BRAF associated autophagy exploitation: BRAF and autophagy inhibitors synergise to efficiently overcome resistance of BRAF mutant colorectal cancer cells.
    Goulielmaki M; Koustas E; Moysidou E; Vlassi M; Sasazuki T; Shirasawa S; Zografos G; Oikonomou E; Pintzas A
    Oncotarget; 2016 Feb; 7(8):9188-221. PubMed ID: 26802026
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The non-peptidomimetic IAP antagonist ASTX660 sensitizes colorectal cancer cells for extrinsic apoptosis.
    Knoll G; Ehrenschwender M
    FEBS Open Bio; 2021 Mar; 11(3):714-723. PubMed ID: 33484626
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Smac mimetic Birinapant induces apoptosis and enhances TRAIL potency in inflammatory breast cancer cells in an IAP-dependent and TNF-α-independent mechanism.
    Allensworth JL; Sauer SJ; Lyerly HK; Morse MA; Devi GR
    Breast Cancer Res Treat; 2013 Jan; 137(2):359-71. PubMed ID: 23225169
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The IAP Protein Family, SMAC Mimetics and Cancer Treatment.
    Philchenkov A; Miura K
    Crit Rev Oncog; 2016; 21(3-4):185-202. PubMed ID: 27915971
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Smac mimetics can provoke lytic cell death that is neither apoptotic nor necroptotic.
    Miles MA; Caruso S; Baxter AA; Poon IKH; Hawkins CJ
    Apoptosis; 2020 Aug; 25(7-8):500-518. PubMed ID: 32440848
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Birinapant (TL32711), a bivalent SMAC mimetic, targets TRAF2-associated cIAPs, abrogates TNF-induced NF-κB activation, and is active in patient-derived xenograft models.
    Benetatos CA; Mitsuuchi Y; Burns JM; Neiman EM; Condon SM; Yu G; Seipel ME; Kapoor GS; Laporte MG; Rippin SR; Deng Y; Hendi MS; Tirunahari PK; Lee YH; Haimowitz T; Alexander MD; Graham MA; Weng D; Shi Y; McKinlay MA; Chunduru SK
    Mol Cancer Ther; 2014 Apr; 13(4):867-79. PubMed ID: 24563541
    [TBL] [Abstract][Full Text] [Related]  

  • 10. NCTD promotes Birinapant-mediated anticancer activity in breast cancer cells by downregulation of c-FLIP.
    Zhao L; Yang G; Bai H; Zhang M; Mou D
    Oncotarget; 2017 Apr; 8(16):26886-26895. PubMed ID: 28460471
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Selective BRAFV600E inhibitor PLX4720, requires TRAIL assistance to overcome oncogenic PIK3CA resistance.
    Oikonomou E; Koc M; Sourkova V; Andera L; Pintzas A
    PLoS One; 2011; 6(6):e21632. PubMed ID: 21738740
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Co-treatment of birinapant with TRAIL synergistically induces apoptosis by downregulating cFLIP(L) in MDA-MB-453 cell lines.
    Park EJ; Kim HD; Choi EK; Hoe KL; Kim DU
    Biochem Biophys Res Commun; 2020 Dec; 533(3):289-295. PubMed ID: 32958259
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination effects of SMAC mimetic birinapant with TNFα, TRAIL, and docetaxel in preclinical models of HNSCC.
    Eytan DF; Snow GE; Carlson SG; Schiltz S; Chen Z; Van Waes C
    Laryngoscope; 2015 Mar; 125(3):E118-24. PubMed ID: 25431358
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic potential and molecular mechanism of a novel, potent, nonpeptide, Smac mimetic SM-164 in combination with TRAIL for cancer treatment.
    Lu J; McEachern D; Sun H; Bai L; Peng Y; Qiu S; Miller R; Liao J; Yi H; Liu M; Bellail A; Hao C; Sun SY; Ting AT; Wang S
    Mol Cancer Ther; 2011 May; 10(5):902-14. PubMed ID: 21372226
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ABT-263 sensitizes TRAIL-resistant hepatocarcinoma cells by downregulating the Bcl-2 family of anti-apoptotic protein.
    Wang G; Zhan Y; Wang H; Li W
    Cancer Chemother Pharmacol; 2012 Mar; 69(3):799-805. PubMed ID: 22037880
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel SMAC-mimetics synergistically stimulate melanoma cell death in combination with TRAIL and Bortezomib.
    Lecis D; Drago C; Manzoni L; Seneci P; Scolastico C; Mastrangelo E; Bolognesi M; Anichini A; Kashkar H; Walczak H; Delia D
    Br J Cancer; 2010 Jun; 102(12):1707-16. PubMed ID: 20461078
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of Bcl-2 or IAP proteins does not provoke mutations in surviving cells.
    Shekhar TM; Green MM; Rayner DM; Miles MA; Cutts SM; Hawkins CJ
    Mutat Res; 2015 Jul; 777():23-32. PubMed ID: 25916945
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The BH3-mimetic ABT-737 sensitizes human melanoma cells to apoptosis induced by selective BRAF inhibitors but does not reverse acquired resistance.
    Wroblewski D; Mijatov B; Mohana-Kumaran N; Lai F; Gallagher SJ; Haass NK; Zhang XD; Hersey P
    Carcinogenesis; 2013 Feb; 34(2):237-47. PubMed ID: 23087082
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antitumor activity of BRAF inhibitor vemurafenib in preclinical models of BRAF-mutant colorectal cancer.
    Yang H; Higgins B; Kolinsky K; Packman K; Bradley WD; Lee RJ; Schostack K; Simcox ME; Kopetz S; Heimbrook D; Lestini B; Bollag G; Su F
    Cancer Res; 2012 Feb; 72(3):779-89. PubMed ID: 22180495
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The caspase-8 inhibitor emricasan combines with the SMAC mimetic birinapant to induce necroptosis and treat acute myeloid leukemia.
    Brumatti G; Ma C; Lalaoui N; Nguyen NY; Navarro M; Tanzer MC; Richmond J; Ghisi M; Salmon JM; Silke N; Pomilio G; Glaser SP; de Valle E; Gugasyan R; Gurthridge MA; Condon SM; Johnstone RW; Lock R; Salvesen G; Wei A; Vaux DL; Ekert PG; Silke J
    Sci Transl Med; 2016 May; 8(339):339ra69. PubMed ID: 27194727
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.